Cargando…

Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives

Neisseria meningitidis causes severe invasive meningococcal diseases (IMDs) in humans including meningitis and septicemia, responsible for serious clinical conditions and leading to life-long disabilities and death. Serogroup B dominates IMDs burden in Italy, accounting for over 60% of total cases....

Descripción completa

Detalles Bibliográficos
Autores principales: SIGNORELLI, C., CHIESA, V., ODONE, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore SPA 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755121/
https://www.ncbi.nlm.nih.gov/pubmed/26788733
_version_ 1782416147696582656
author SIGNORELLI, C.
CHIESA, V.
ODONE, A.
author_facet SIGNORELLI, C.
CHIESA, V.
ODONE, A.
author_sort SIGNORELLI, C.
collection PubMed
description Neisseria meningitidis causes severe invasive meningococcal diseases (IMDs) in humans including meningitis and septicemia, responsible for serious clinical conditions and leading to life-long disabilities and death. Serogroup B dominates IMDs burden in Italy, accounting for over 60% of total cases. On January 2013 the European Medicine Agency (EMA) licensed the first serogroup B meningococcal (MenB) vaccine in Europe. A number of European countries and Regions have introduced the new MenB vaccine in their immunization schedule, including Italy. In this paper we present the state of art, related critical issues and future perspectives of MenB vaccine introduction in Italy, in the context of the most recent available epidemiological data. In particular, we systematically assess the ongoing processes in the 8 Italian regions and one autonomous province that have already introduced MenB vaccine. With the new 2014-2018 National Vaccine Prevention Plan including active MenB vaccine offer about to be adopted, it is of fundamental importance to gather further evidence on MenB vaccine clinical effectiveness, duration of protection and cost-effectiveness. Italian regions are called to organize and manage MenB immunization programs. Careful consideration will need to be devoted on timing, doses, and co-administration with other vaccines but also to economic assessments and strengthened communication to the general public. Our data will help to plan, implement and evaluate MenB immunization programmes in other Italian and international settings.
format Online
Article
Text
id pubmed-4755121
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Pacini Editore SPA
record_format MEDLINE/PubMed
spelling pubmed-47551212016-02-19 Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives SIGNORELLI, C. CHIESA, V. ODONE, A. J Prev Med Hyg Review Neisseria meningitidis causes severe invasive meningococcal diseases (IMDs) in humans including meningitis and septicemia, responsible for serious clinical conditions and leading to life-long disabilities and death. Serogroup B dominates IMDs burden in Italy, accounting for over 60% of total cases. On January 2013 the European Medicine Agency (EMA) licensed the first serogroup B meningococcal (MenB) vaccine in Europe. A number of European countries and Regions have introduced the new MenB vaccine in their immunization schedule, including Italy. In this paper we present the state of art, related critical issues and future perspectives of MenB vaccine introduction in Italy, in the context of the most recent available epidemiological data. In particular, we systematically assess the ongoing processes in the 8 Italian regions and one autonomous province that have already introduced MenB vaccine. With the new 2014-2018 National Vaccine Prevention Plan including active MenB vaccine offer about to be adopted, it is of fundamental importance to gather further evidence on MenB vaccine clinical effectiveness, duration of protection and cost-effectiveness. Italian regions are called to organize and manage MenB immunization programs. Careful consideration will need to be devoted on timing, doses, and co-administration with other vaccines but also to economic assessments and strengthened communication to the general public. Our data will help to plan, implement and evaluate MenB immunization programmes in other Italian and international settings. Pacini Editore SPA 2015-08 /pmc/articles/PMC4755121/ /pubmed/26788733 Text en © Copyright by Pacini Editore SPA, Pisa, Italy http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Review
SIGNORELLI, C.
CHIESA, V.
ODONE, A.
Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
title Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
title_full Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
title_fullStr Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
title_full_unstemmed Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
title_short Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
title_sort meningococcal serogroup b vaccine in italy: state-of-art, organizational aspects and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755121/
https://www.ncbi.nlm.nih.gov/pubmed/26788733
work_keys_str_mv AT signorellic meningococcalserogroupbvaccineinitalystateofartorganizationalaspectsandperspectives
AT chiesav meningococcalserogroupbvaccineinitalystateofartorganizationalaspectsandperspectives
AT odonea meningococcalserogroupbvaccineinitalystateofartorganizationalaspectsandperspectives